PMC:4385186 / 3921-5599 JSONTXT

{"project":"2_test","denotations":[{"id":"25839328-24670651-2052565","span":{"begin":1389,"end":1390},"obj":"24670651"},{"id":"25839328-24670651-2052566","span":{"begin":1589,"end":1590},"obj":"24670651"}],"text":"Samples and Clinical Data\nTumor samples and adjacent, histologically normal tissues were obtained from 104 ESCC-affected individuals recruited from the Taihang Mountains of north-central China. All individuals gave their informed consent, and all samples were obtained before treatment according to the guidelines of the institutional review board of Shanxi Medical University (approval no. 2009029) and the ethics committee of Henan Cancer Hospital (approval no. 2009xjs12). The tumor samples of all affected individuals had at least 40%–50% of tumor cell content. This study was approved by the ethics committees of the Shanxi Medical University and Henan Cancer Hospital. The ESCC individuals collected for this study were staged according to the Cancer Staging Standards of the American Joint Committee on Cancer (seventh edition, 2010). The cohort of 104 ESCC individuals included 96 smoking and 8 non-smoking individuals. Different subsets of individuals were assayed on each platform: 14 tumors and 14 matched normal samples had data available on WGS (65× coverage), and 90 samples had data available on WES (132× coverage); in addition, 96 of the 104 samples had target capture deep resequencing (365× coverage). A detailed description of the clinical characteristics of the analyzed samples is presented in Table S1. We also analyzed our previously published ESCC mutation dataset6 of 17 WGS and 71 WES samples recruited from the Chaoshan District of Gongdong Province, another area of high ESCC prevalence in China. This cohort included 57 smoking and 31 non-smoking individuals.6 The summary of next-generation sequencing analyses in this study is shown in Figure S1."}